



RESPONSE UNDER 37 C.F.R. §1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: FRIDKIN et al

Application No.: 09/117,380

Filed: January 27, 1999

For: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN

Art Unit: 1652

Examiner: R. Hutson

Washington, D.C.

Atty.'s Docket: FRIDKIN=1

Date: July 27, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [] Amendment [XX] Response

in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[] No additional fee is required.

[XX] The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 11	MINUS ** 20	0
INDEP.	* 1	MINUS *** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 80	\$
+ 270	\$
TOTAL	

OR

OR

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [] First - \$ 55.00
- [XX] Second - \$ 195.00
- [] Third - \$ 445.00
- [] Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- [] First - \$ 110.00
- [] Second - \$ 390.00
- [] Third - \$ 890.00
- [] Fourth - \$ 1390.00

Month After Time Period Set

[] Less fees (\$_____) already paid for ____ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.


[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$195.00.

[] A check in the amount of \$_____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
ROGER L. BROWDY
Registration No. 25,618

JUL 21 2001

1.

4/9/1 (Item 1 from file: 5)

11090606 & Biosis No.: 199799711751

Inhibition of human leukocyte elastase and cathepsin G by extended peptides and subunits derived from human C-reactive protein.TECH CENTER
1600/2600

AUG 01 2001

RECEIVED

Author: Yavin Eran J; Yan Lin; Desiderio Dominic M; Pontet Michel; Fridkin Matia**Author Address:** (a)Dep. Organic Chem., Weizmann Inst. Sci., Rehovot 76100**Israel**Journal:** Letters in Peptide Science 4 (3): p 157-166 1997**ISSN:** 0929-5666**Record Type:** Abstract**Language:** English

Abstract: Extended peptides that derive from the primary sequence of the acute phase reactant C-reactive protein (CRP) are shown to inhibit in vitro the enzymatic activities of human leukocyte elastase (hLE) and human leukocyte cathepsin G (hCG), which are associated with the tissue damage that occurs during the course of several chronic inflammatory conditions. Major inhibitory activity was observed in the peptides CRP-70-98 and CRP-50-98 towards hLE ($K_i = 4.0 \text{ mu-M}$) and hCG ($K_i = 1.4 \text{ mu-M}$), respectively. In contrast to the inability of intact CRP pentamers to inhibit both enzymes, CRP subunits (monomers) inhibited hLE (3.0 mu-M) and hCG (3.6 mu-M) activity.

Registry Numbers: 9004-06-2: ELASTASE; 56645-49-9: CATHEPSIN G; 37205-61-1D: PROTEASE INHIBITORS**Descriptors:****Major Concepts:** Biochemistry and Molecular Biophysics; Blood and Lymphatics (Transport and Circulation); Enzymology (Biochemistry and Molecular Biophysics); Pathology ; Pharmacology**Biosystematic Names:** Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia**Organisms:** human (Hominidae)**Biosystematic Classification (super Taxa):** animals; chordates; humans; mammals; primates; vertebrates**Chemicals & Biochemicals:** ELASTASE; CATHEPSIN G; PROTEASE INHIBITORS**Miscellaneous Terms:** Research Article; ANTIINFLAMMATORY AGENTS; BLOOD AND LYMPHATICS; C-REACTIVE PROTEIN-DERIVED PEPTIDES; CATHEPSIN G; ELASTASE; ENZYMOLOGY; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTES; PHARMACOLOGY; PROTEASE INHIBITORS**Concept Codes:**

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

10806 Enzymes-Chemical and Physical

12508 Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease

15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies

22002 Pharmacology-General

Biosystematic Codes:**Biosystematic Codes:** 86215 Hominidae

Biosis Previews(R) (Dialog® File 5): (c) 2001 BIOSIS. All rights reserved.